Strategic Partnerships Prellis Biologics has a history of high-profile collaborations with major pharma players such as Bristol Myers Squibb and Sanofi, and is actively expanding its Immunology EXIS platform for antibody discovery and vaccine screening. Sales opportunities exist in partnering with large biopharma to co-develop or license antibody discovery capabilities and immunogenicity assessment.

Clinical Development Alignment Recent and ongoing development of human antibody therapeutics in collaboration with Lilly indicates a focus on targeted therapeutic programs. This presents a selling point for enabling platforms that accelerate target validation, antibody discovery, and preclinical screening to de-risk and shorten timelines for clinical programs.

Platform Expansion EXIS platform is being expanded to integrate applications across antibody discovery, immunogenicity evaluation, and vaccine screening. There is a sales opportunity to position EXIS as a comprehensive, one-stop platform for end-to-end immunology workflows, appealing to research groups seeking consolidated tooling.

Investment Backing With a substantial funding history including a $35M Series C and a total funding of $79M, the company demonstrates strong investor confidence and growth trajectory. This signals potential readiness to invest in scalable collaborations, pilot projects, or co-development agreements that align with funding-driven milestones.

Digital and Ops Readiness Adoption of modern tech stack (AWS, Asana, Jira, Google Workspace) and cloud-enabled operations suggests a mature, scalable commercialization path. This can be leveraged to offer scalable cloud-based services, data management support, and joint optimization of computational workflows for partner programs.